Vanda Pharmaceuticals Inc (VNDA) - Total Liabilities
Based on the latest financial reports, Vanda Pharmaceuticals Inc (VNDA) has total liabilities worth $161.76 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Vanda Pharmaceuticals Inc net asset momentum to track the company's year-over-year net asset growth rate.
Vanda Pharmaceuticals Inc - Total Liabilities Trend (2004–2025)
This chart illustrates how Vanda Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Vanda Pharmaceuticals Inc generate to measure how efficiently the company converts operating cash flow to free cash.
Vanda Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Vanda Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WITHSECURE
HE:WITH
|
Finland | €99.79 Million |
|
Rubellite Energy Inc
TO:RBY
|
Canada | CA$234.57 Million |
|
Korea Environment Technology Co. LTD
KQ:029960
|
Korea | ₩53.13 Billion |
|
Sichuan Huiyuan Optical Com
SHE:000586
|
China | CN¥292.99 Million |
|
Delta Plus Group SA
PA:ALDLT
|
France | €261.79 Million |
|
Novabase SGPS
LS:NBA
|
Portugal | €67.20 Million |
|
Cybin Inc
NEO:CYBN
|
Canada | CA$16.18 Million |
|
Sonda S.A
SN:SONDA
|
Chile | CL$873.83 Billion |
Liability Composition Analysis (2004–2025)
This chart breaks down Vanda Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Vanda Pharmaceuticals Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vanda Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vanda Pharmaceuticals Inc (2004–2025)
The table below shows the annual total liabilities of Vanda Pharmaceuticals Inc from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $161.76 Million | +37.48% |
| 2024-12-31 | $117.66 Million | +13.65% |
| 2023-12-31 | $103.53 Million | -3.29% |
| 2022-12-31 | $107.05 Million | +20.46% |
| 2021-12-31 | $88.86 Million | +10.82% |
| 2020-12-31 | $80.19 Million | +10.15% |
| 2019-12-31 | $72.80 Million | +28.38% |
| 2018-12-31 | $56.71 Million | -23.41% |
| 2017-12-31 | $74.04 Million | -6.33% |
| 2016-12-31 | $79.04 Million | -1.22% |
| 2015-12-31 | $80.02 Million | +635.03% |
| 2014-12-31 | $10.89 Million | -89.03% |
| 2013-12-31 | $99.22 Million | -20.96% |
| 2012-12-31 | $125.54 Million | -15.82% |
| 2011-12-31 | $149.14 Million | -14.96% |
| 2010-12-31 | $175.37 Million | -13.48% |
| 2009-12-31 | $202.68 Million | +5078.99% |
| 2008-12-31 | $3.91 Million | -70.20% |
| 2007-12-31 | $13.13 Million | +38.18% |
| 2006-12-31 | $9.50 Million | +86.78% |
| 2005-12-31 | $5.09 Million | +181.31% |
| 2004-12-31 | $1.81 Million | -- |
About Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nightt… Read more